Search

for
Search:

GlossaryGefitinib (ZD1839)

inhibits EGFR to treat certain non-small cell lung cancers

Gefitinib, also known as Iressa, is a medication used to treat certain types of non-small cell lung cancer. It works by inhibiting the epidermal growth factor receptor (EGFR), which is involved in the growth and spread of cancer cells. By blocking this receptor, gefitinib can help slow down or stop the progression of the cancer.

Related Terms

Learn

0 / 0 results

— no results

Research

5 / 26 results

research Follicular and Epidermal Alterations in Patients Treated with ZD1839 (Iressa), an Inhibitor of the Epidermal Growth Factor Receptor

169 citations, September 2002 in “British journal of dermatology/British journal of dermatology, Supplement”

ZD1839 (Iressa) causes skin and hair side effects, treatable with tretinoin cream and minocycline.

research Acneiform Eruptions Caused by an Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor ZD1839

1 citations, March 2004 in “Journal of the American Academy of Dermatology”

ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.

research Rash from EGFR Inhibitors: Opportunities and Challenges for Palliation

18 citations, July 2008 in “Current Oncology Reports”

EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.

research Skin Toxicity of Anti-Cancer Therapy

19 citations, October 2008 in “Journal der Deutschen Dermatologischen Gesellschaft”

Anti-cancer treatments can cause reversible hair loss, skin sensitivity, pigmentation changes, nail damage, and skin reactions, with a need for more research on managing these side effects.

research Non-Rash Skin Toxicities Associated with Novel Targeted Therapies

28 citations, December 2006 in “Clinical lung cancer”

Early recognition and management of skin side effects from new cancer therapies can prevent treatment delays.

View more "zd1839" in research →

Community Join

0 / 0 results

— no results